skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 1,047  for All Library Resources

Sorted by: Sorted by: Date-newestOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: Business Wire remove subject: Product Development remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
Material Type:
Newspaper Article 		Add to My Research

Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
2
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Material Type:
Newspaper Article 		Add to My Research

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Business Wire, 2024-06-03

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
3
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Material Type:
Newspaper Article 		Add to My Research

Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
4
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Material Type:
Newspaper Article 		Add to My Research

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Business Wire, 2024-06-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
5
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
Material Type:
Newspaper Article 		Add to My Research

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Business Wire, 2024-05-29

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
6
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Material Type:
Newspaper Article 		Add to My Research

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Business Wire, 2024-05-27

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
7
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Material Type:
Newspaper Article 		Add to My Research

Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

Business Wire, 2024-05-23

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
8
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Material Type:
Newspaper Article 		Add to My Research

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Business Wire, 2024-05-08

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
9
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
Material Type:
Newspaper Article 		Add to My Research

CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Business Wire, 2024-05-02

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
10
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Material Type:
Newspaper Article 		Add to My Research

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Business Wire, 2024-04-26

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
11
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Material Type:
Newspaper Article 		Add to My Research

Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Business Wire, 2024-04-22

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
12
Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Material Type:
Newspaper Article 		Add to My Research

Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Business Wire, 2024-04-11

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
13
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Material Type:
Newspaper Article 		Add to My Research

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Business Wire, 2024-04-09

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
14
IMFINZI (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
IMFINZI (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
Material Type:
Newspaper Article 		Add to My Research

IMFINZI (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Business Wire, 2024-04-05

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
15
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Material Type:
Newspaper Article 		Add to My Research

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Business Wire, 2024-04-04

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
16
AstraZeneca announces initiation of THARROS - a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
AstraZeneca announces initiation of THARROS - a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
Material Type:
Newspaper Article 		Add to My Research

AstraZeneca announces initiation of THARROS - a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

Business Wire, 2024-03-13

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
17
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Material Type:
Newspaper Article 		Add to My Research

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Business Wire, 2024-03-06

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
18
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Material Type:
Newspaper Article 		Add to My Research

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Business Wire, 2024-03-01

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
19
Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com
Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com
Material Type:
Newspaper Article 		Add to My Research

Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com

Business Wire, 2024-02-27

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by
20
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Material Type:
Newspaper Article 		Add to My Research

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Business Wire, 2024-02-23

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

Citations Cited by

Results 1 - 20 of 1,047  for All Library Resources

Sorted by: Sorted by: Date-newestOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2005  (9)
  2. 2005 To 2008  (77)
  3. 2009 To 2012  (204)
  4. 2013 To 2017  (318)
  5. After 2017  (440)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait